PLoS ONE (Jan 2011)

Selenium and lung cancer: a systematic review and meta analysis.

  • Heidi Fritz,
  • Deborah Kennedy,
  • Dean Fergusson,
  • Rochelle Fernandes,
  • Kieran Cooley,
  • Andrew Seely,
  • Stephen Sagar,
  • Raimond Wong,
  • Dugald Seely

DOI
https://doi.org/10.1371/journal.pone.0026259
Journal volume & issue
Vol. 6, no. 11
p. e26259

Abstract

Read online

BackgroundSelenium is a natural health product widely used in the treatment and prevention of lung cancers, but large chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and assessed potential interactions with conventional therapies.Methods and findingsTwo independent reviewers searched six databases from inception to March 2009 for evidence pertaining to the safety and efficacy of selenium for lung cancers. Pubmed and EMBASE were searched to October 2009 for evidence on interactions with chemo- or radiation-therapy. In the efficacy analysis there were nine reports of five RCTs and two biomarker-based studies, 29 reports of 26 observational studies, and 41 preclinical studies. Fifteen human studies, one case report, and 36 preclinical studies were included in the interactions analysis. Based on available evidence, there appears to be a different chemopreventive effect dependent on baseline selenium status, such that selenium supplementation may reduce risk of lung cancers in populations with lower baseline selenium status (serumConclusionsSelenium may be effective for lung cancer prevention among individuals with lower selenium status, but at present should not be used as a general strategy for lung cancer prevention. Although promising, more evidence on the ability of selenium to reduce cisplatin and radiation therapy toxicity is required to ensure that therapeutic efficacy is maintained before any broad clinical recommendations can be made in this context.